Novartis has a long way to go to make its twice-yearly cholesterol-lowering drug Leqvio the multi-billion-dollar blockbuster it is predicting – but took another step along that road today.

Evolucumab (Repatha) and alirocumab (Praluent) are injectable monoclonal antibodies. They have been joined by inclisiran ...

Novartis' strong drug pipeline and financials support an 11% annual return by 2027. Learn why NVS stock offers 33% return ...

Q. Allergan ran a long-term study on silicone breast implants in 2009. I always wanted a more feminine body like the girls in the magazines, so I joined and got implants. They never followed up with ...

AstraZeneca has taken the decision not to move a PCSK9-targeting antisense drug licensed from Ionis into a phase 3 programme, removing a competitor to Novartis' rival therapy Leqvio. Like Leqvio ...

These drugs reduce the cholesterol your body makes ... alirocumab (Praluent), evolocumab (Repatha), and inclisiran (Leqvio)-- are injections that keep LDL receptors free to bind to LDL cholesterol ...

ALNY reports better-than-expected fourth-quarter results as both earnings and revenues beat estimates driven by higher ...